Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Alteration of cellular behavior and response to PI3K pathway inhibition by culture in 3D collagen gels.

Fallica B, Maffei JS, Villa S, Makin G, Zaman M.

PLoS One. 2012;7(10):e48024. doi: 10.1371/journal.pone.0048024. Epub 2012 Oct 23.

2.

Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.

Guenther MK, Graab U, Fulda S.

Cancer Lett. 2013 Sep 1;337(2):200-9. doi: 10.1016/j.canlet.2013.05.010. Epub 2013 May 16.

PMID:
23684925
3.

Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.

Chen G, Chen SM, Wang X, Ding XF, Ding J, Meng LH.

J Biol Chem. 2012 Apr 6;287(15):12132-41. doi: 10.1074/jbc.M111.302299. Epub 2012 Feb 15. Erratum in: J Biol Chem. 2012 Jun 1;287(23):19336.

4.

HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment.

Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ.

Breast Cancer Res Treat. 2010 Jul;122(1):35-43. doi: 10.1007/s10549-009-0502-2. Epub 2009 Aug 22.

5.

Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.

Bhattacharya B, Akram M, Balasubramanian I, Tam KK, Koh KX, Yee MQ, Soong R.

Cancer Biol Ther. 2012 Jan 1;13(1):34-42. doi: 10.4161/cbt.13.1.18437.

PMID:
22336586
6.

Inhibition of phosphatidylinositol 3-kinase signaling in hepatic stellate cells blocks the progression of hepatic fibrosis.

Son G, Hines IN, Lindquist J, Schrum LW, Rippe RA.

Hepatology. 2009 Nov;50(5):1512-23. doi: 10.1002/hep.23186.

7.

Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma.

Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z.

PLoS One. 2014 Apr 2;9(4):e93996. doi: 10.1371/journal.pone.0093996. eCollection 2014.

8.

Chloroquine overcomes resistance of lung carcinoma cells to the dual PI3K/mTOR inhibitor PI103 by lysosome-mediated apoptosis.

Enzenmüller S, Gonzalez P, Debatin KM, Fulda S.

Anticancer Drugs. 2013 Jan;24(1):14-9. doi: 10.1097/CAD.0b013e32835a36db.

PMID:
23111416
9.

Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway.

Xu HY, Chen ZW, Hou JC, Du FX, Liu JC.

Oncol Rep. 2013 Jan;29(1):212-8. doi: 10.3892/or.2012.2113. Epub 2012 Oct 31.

PMID:
23129237
10.

PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.

Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.

Anticancer Res. 2010 Dec;30(12):4951-8.

11.

Toward single cell traction microscopy within 3D collagen matrices.

Hall MS, Long R, Feng X, Huang Y, Hui CY, Wu M.

Exp Cell Res. 2013 Oct 1;319(16):2396-408. doi: 10.1016/j.yexcr.2013.06.009. Epub 2013 Jun 25. Review.

12.

PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.

Shepherd C, Banerjee L, Cheung CW, Mansour MR, Jenkinson S, Gale RE, Khwaja A.

Leukemia. 2013 Mar;27(3):650-60. doi: 10.1038/leu.2012.285. Epub 2012 Oct 5.

PMID:
23038273
13.

Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.

Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S.

Clin Cancer Res. 2011 Apr 15;17(8):2260-9. doi: 10.1158/1078-0432.CCR-10-1993. Epub 2011 Jan 10.

14.

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.

Chiarini F, Falà F, Tazzari PL, Ricci F, Astolfi A, Pession A, Pagliaro P, McCubrey JA, Martelli AM.

Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.

15.

Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.

Zou CY, Smith KD, Zhu QS, Liu J, McCutcheon IE, Slopis JM, Meric-Bernstam F, Peng Z, Bornmann WG, Mills GB, Lazar AJ, Pollock RE, Lev D.

Mol Cancer Ther. 2009 May;8(5):1157-68. doi: 10.1158/1535-7163.MCT-08-1008. Epub 2009 May 5.

16.

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.

Yothaisong S, Dokduang H, Techasen A, Namwat N, Yongvanit P, Bhudhisawasdi V, Puapairoj A, Riggins GJ, Loilome W.

Tumour Biol. 2013 Dec;34(6):3637-48. doi: 10.1007/s13277-013-0945-2. Epub 2013 Jul 6.

PMID:
23832540
17.

A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses.

Härmä V, Virtanen J, Mäkelä R, Happonen A, Mpindi JP, Knuuttila M, Kohonen P, Lötjönen J, Kallioniemi O, Nees M.

PLoS One. 2010 May 3;5(5):e10431. doi: 10.1371/journal.pone.0010431.

18.

Divalent cations modulate alpha2beta1 integrin-mediated malignancy in a novel 3-dimensional in vitro model of pancreatic cancer.

Grzesiak JJ, Vargas F, Bouvet M.

Pancreas. 2010 Aug;39(6):904-12. doi: 10.1097/MPA.0b013e3181ce60a3.

19.

Impact of the 3D microenvironment on phenotype, gene expression, and EGFR inhibition of colorectal cancer cell lines.

Luca AC, Mersch S, Deenen R, Schmidt S, Messner I, Schäfer KL, Baldus SE, Huckenbeck W, Piekorz RP, Knoefel WT, Krieg A, Stoecklein NH.

PLoS One. 2013;8(3):e59689. doi: 10.1371/journal.pone.0059689. Epub 2013 Mar 26.

20.

Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.

Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S, Henley A, Di-Stefano F, Ahmad Z, Guillard S, Bjerke LM, Kelland L, Valenti M, Patterson L, Gowan S, de Haven Brandon A, Hayakawa M, Kaizawa H, Koizumi T, Ohishi T, Patel S, Saghir N, Parker P, Waterfield M, Workman P.

Cancer Res. 2007 Jun 15;67(12):5840-50.

Items per page

Supplemental Content

Write to the Help Desk